ASCO 2024: Updates in Multiple Myeloma : Episode 2
Opinion
Video
Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.
EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
Now Viewing
EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EP: 6.Future Directions in the Management of Multiple Myeloma
Video content above is prompted by the following:
- Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Related Videos
Related Content
